Preventing Graft-versus-Host Disease After Donor Cell Infusion
Part of Immune system & allergy clinical trials.
This trial tests two different medicines to prevent graft-versus-host disease (a condition where donor cells attack your body) after a donor lymphocyte infusion. The goal is to make the treatment safer and more effective for patients whose blood cancer has returned after a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer that came back after a stem cell transplant from a donor who was not a perfectly matched sibling.
- Your doctor plans to give you a donor lymphocyte infusion (white blood cells from your donor) as part of your treatment.
- You are generally able to care for yourself (ECOG score 0-2).
- You do not have other active cancers that need treatment.
- You do not have active infections like hepatitis B, hepatitis C, or tuberculosis, and you are not HIV-positive.
- You are not pregnant and are willing to use contraception during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.